A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients

L. A. Green-Gallo, D. M. Buivys, K. L. Fisher, N. Caporaso, R. G. Slawson, E. G. Elias, M. S. Didolkar, W. J. Ivusich, J. H. Resau

Research output: Contribution to journalArticle

Abstract

The genetically determined ability to metabolize the antihypertensive drug debrisoquine has been proposed as a genetic risk factor for primary carcinomas of the lung. To test this hypothesis, the metabolism of the drug was evaluated in a case control study. The subjects were characterized by their ability to metabolize debrisoquine after receiving a test dose of the drug followed by the collection of an 8-hour urine sample. They were classified by laboratory analysis into one of the following three groups: extensive, intermediate, and poor metabolizers. Poor metabolizers comprise 10% of the population and are unable to hydroxylate the drug. This group was expected to be at highest risk for deleterious effects from this medication. A protocol was created that included patient education and blood pressure monitoring to administer this medication safely to a group of patients with cancer who were already compromised. Although poor metabolizers showed a small decrease in systolic and diastolic blood pressure, no significant hypotensive episodes or clinical sequelae were observed in any of the groups. These data suggest that debrisoquine can be administered safely in a controlled clinical setting and will be useful for the characterization of lung cancer patients in biochemical epidemiology studies.

Original languageEnglish (US)
Pages (from-to)206-210
Number of pages5
JournalCancer
Volume68
Issue number1
StatePublished - 1991
Externally publishedYes

Fingerprint

Debrisoquin
Blood Pressure
Research
Pharmaceutical Preparations
Patient Education
Antihypertensive Agents
Case-Control Studies
Lung Neoplasms
Epidemiology
Urine
Carcinoma
Lung
Population
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Green-Gallo, L. A., Buivys, D. M., Fisher, K. L., Caporaso, N., Slawson, R. G., Elias, E. G., ... Resau, J. H. (1991). A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients. Cancer, 68(1), 206-210.

A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients. / Green-Gallo, L. A.; Buivys, D. M.; Fisher, K. L.; Caporaso, N.; Slawson, R. G.; Elias, E. G.; Didolkar, M. S.; Ivusich, W. J.; Resau, J. H.

In: Cancer, Vol. 68, No. 1, 1991, p. 206-210.

Research output: Contribution to journalArticle

Green-Gallo, LA, Buivys, DM, Fisher, KL, Caporaso, N, Slawson, RG, Elias, EG, Didolkar, MS, Ivusich, WJ & Resau, JH 1991, 'A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients', Cancer, vol. 68, no. 1, pp. 206-210.
Green-Gallo LA, Buivys DM, Fisher KL, Caporaso N, Slawson RG, Elias EG et al. A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients. Cancer. 1991;68(1):206-210.
Green-Gallo, L. A. ; Buivys, D. M. ; Fisher, K. L. ; Caporaso, N. ; Slawson, R. G. ; Elias, E. G. ; Didolkar, M. S. ; Ivusich, W. J. ; Resau, J. H. / A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients. In: Cancer. 1991 ; Vol. 68, No. 1. pp. 206-210.
@article{66a6d851830c48e6abbe89b0e91b510e,
title = "A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients",
abstract = "The genetically determined ability to metabolize the antihypertensive drug debrisoquine has been proposed as a genetic risk factor for primary carcinomas of the lung. To test this hypothesis, the metabolism of the drug was evaluated in a case control study. The subjects were characterized by their ability to metabolize debrisoquine after receiving a test dose of the drug followed by the collection of an 8-hour urine sample. They were classified by laboratory analysis into one of the following three groups: extensive, intermediate, and poor metabolizers. Poor metabolizers comprise 10{\%} of the population and are unable to hydroxylate the drug. This group was expected to be at highest risk for deleterious effects from this medication. A protocol was created that included patient education and blood pressure monitoring to administer this medication safely to a group of patients with cancer who were already compromised. Although poor metabolizers showed a small decrease in systolic and diastolic blood pressure, no significant hypotensive episodes or clinical sequelae were observed in any of the groups. These data suggest that debrisoquine can be administered safely in a controlled clinical setting and will be useful for the characterization of lung cancer patients in biochemical epidemiology studies.",
author = "Green-Gallo, {L. A.} and Buivys, {D. M.} and Fisher, {K. L.} and N. Caporaso and Slawson, {R. G.} and Elias, {E. G.} and Didolkar, {M. S.} and Ivusich, {W. J.} and Resau, {J. H.}",
year = "1991",
language = "English (US)",
volume = "68",
pages = "206--210",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - A protocol for the safe administration of debrisoquine in biochemical epidemiologic research protocols for hospitalized patients

AU - Green-Gallo, L. A.

AU - Buivys, D. M.

AU - Fisher, K. L.

AU - Caporaso, N.

AU - Slawson, R. G.

AU - Elias, E. G.

AU - Didolkar, M. S.

AU - Ivusich, W. J.

AU - Resau, J. H.

PY - 1991

Y1 - 1991

N2 - The genetically determined ability to metabolize the antihypertensive drug debrisoquine has been proposed as a genetic risk factor for primary carcinomas of the lung. To test this hypothesis, the metabolism of the drug was evaluated in a case control study. The subjects were characterized by their ability to metabolize debrisoquine after receiving a test dose of the drug followed by the collection of an 8-hour urine sample. They were classified by laboratory analysis into one of the following three groups: extensive, intermediate, and poor metabolizers. Poor metabolizers comprise 10% of the population and are unable to hydroxylate the drug. This group was expected to be at highest risk for deleterious effects from this medication. A protocol was created that included patient education and blood pressure monitoring to administer this medication safely to a group of patients with cancer who were already compromised. Although poor metabolizers showed a small decrease in systolic and diastolic blood pressure, no significant hypotensive episodes or clinical sequelae were observed in any of the groups. These data suggest that debrisoquine can be administered safely in a controlled clinical setting and will be useful for the characterization of lung cancer patients in biochemical epidemiology studies.

AB - The genetically determined ability to metabolize the antihypertensive drug debrisoquine has been proposed as a genetic risk factor for primary carcinomas of the lung. To test this hypothesis, the metabolism of the drug was evaluated in a case control study. The subjects were characterized by their ability to metabolize debrisoquine after receiving a test dose of the drug followed by the collection of an 8-hour urine sample. They were classified by laboratory analysis into one of the following three groups: extensive, intermediate, and poor metabolizers. Poor metabolizers comprise 10% of the population and are unable to hydroxylate the drug. This group was expected to be at highest risk for deleterious effects from this medication. A protocol was created that included patient education and blood pressure monitoring to administer this medication safely to a group of patients with cancer who were already compromised. Although poor metabolizers showed a small decrease in systolic and diastolic blood pressure, no significant hypotensive episodes or clinical sequelae were observed in any of the groups. These data suggest that debrisoquine can be administered safely in a controlled clinical setting and will be useful for the characterization of lung cancer patients in biochemical epidemiology studies.

UR - http://www.scopus.com/inward/record.url?scp=0026321428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026321428&partnerID=8YFLogxK

M3 - Article

C2 - 2049747

AN - SCOPUS:0026321428

VL - 68

SP - 206

EP - 210

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -